Le alternative terapeutiche nell’endometriosi

The paper reviews therapeutic alternatives for endometriosis, discussing how treatment choice depends on symptom severity, extent of disease, age, and reproductive goals, contrasting expectant management in minimal/lite disease with active intervention for severe pain or major anatomic-functional compromise. It summarizes surgical approaches (with emphasis on laparoscopic excision/ablation to reduce pain and the quality-of-life improvements but noting recurrence within 5 years in about one in five) and medical options (combined: suppressive therapies with oral contraceptives, progestins, danazol, gestrinone, and GnRH analogs; plus limitations including poor utility for short-term pregnancy goals, recurrence after stopping within ~6 months, and tolerability issues). It highlights emerging strategies targeting local steroid/immune/inflammatory pathways, including LNG intrauterine devices after conservative surgery, and investigational drug classes such as aromatase inhibitors, SERMs/PRMs, immunomodulators, COX-2 inhibitors, anti-inflammatory agents like pentoxifylline, with the stated caveat that many modalities have only pilot or insufficient human data regarding disease eradication and long-term effects. This paper is centrally about endometriosis — it reviews surgical and medical therapeutic alternatives, including emerging targeted approaches and limitations of current suppressive treatments.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works